STOCK TITAN

Arcturus Therapeutics Holdings Inc. - ARCT STOCK NEWS

Welcome to our dedicated page for Arcturus Therapeutics Holdings news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therapeutics Holdings stock.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), founded in 2013 and based in San Diego, California, is a pioneering RNA medicines company focused on developing novel therapeutics for rare diseases, particularly those with no adequate treatments. Specializing in RNA interference (RNAi) technologies, Arcturus is at the forefront of creating breakthrough treatments aimed at liver and respiratory diseases.

Arcturus operates primarily in the research and development sector, focusing on nucleic acid-based medical applications. Core technologies include its proprietary LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA), enabling a versatile range of RNA therapeutics. Its mRNA drug substance and product manufacturing expertise further position Arcturus as a leader in RNA-based solutions.

Key projects in Arcturus' pipeline include:

  • LUNAR-OTC for treating ornithine transcarbamylase deficiency
  • LUNAR-CF aimed at cystic fibrosis
  • LUNAR-FLU and LUNAR-COV19 for influenza and COVID-19 vaccines respectively

Recently, Arcturus announced a collaborative research endeavor with PassPort Technologies Inc. (PPTI) to explore innovative mRNA formulations and transdermal delivery methods for vaccines and therapeutics. This partnership leverages ARCT’s LUNAR® platform and PPTI’s PassPort® transdermal technology, aiming to enhance the delivery and efficacy of RNA-based treatments.

Further cementing its competitive edge, Arcturus has developed Kostaive®, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine. Arcturus continues its global collaboration with CSL Seqirus for mRNA vaccines and maintains a joint venture in Japan, ARCALIS, to manufacture mRNA vaccines and therapeutics. The company’s extensive patent portfolio, covering over 400 patents across the U.S., Europe, Japan, China, and other countries, underscores its innovative prowess.

Financially, Arcturus maintains a solid growth trajectory, driven by its robust research initiatives and strategic alliances. For more detailed information, visit their official website at www.ArcturusRx.com, and connect via Twitter and LinkedIn.

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a global mRNA medicines company, has announced it will release its financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company will also host a conference call and webcast at 4:30 pm Eastern Time on the same day to discuss the results.

Arcturus focuses on developing infectious disease vaccines and medicines for liver and respiratory rare diseases. Investors and interested parties can join the earnings call using the provided domestic and international phone numbers or access the webcast through the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
conferences earnings
-
Rhea-AI Summary

Arcturus Therapeutics (ARCT), a company specializing in mRNA medicines, provided updates on its ARCT-810 and ARCT-032 programs. The ARCT-810 Phase 2 study for OTC deficiency completed enrollment in Europe, with data expected later this year. This program is expanding in the U.S. to include more severely affected patients. ARCT-032, aimed at treating cystic fibrosis (CF), will submit an IND for a Phase 2 multiple ascending dose study within 60 days, based on positive safety data from previous trials. Key updates include the completion of subject enrollment in Europe for ARCT-810, the expansion of this program in the U.S., and promising preliminary results for ARCT-032 in treating CF patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.21%
Tags
none
-
Rhea-AI Summary

Arcturus Therapeutics (Nasdaq: ARCT) has announced the appointment of Dr. Moncef Slaoui to its Board of Directors. Dr. Slaoui, known for his role as Chief Scientific Advisor for Operation Warp Speed, brings extensive experience in pharmaceutical innovation, development, and commercialization. He has held numerous leadership positions, including at GlaxoSmithKline, where he was instrumental in the development of 14 new vaccines. Dr. Slaoui aims to advance Arcturus' pipeline of mRNA vaccines and therapeutics using next-generation technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
management
Rhea-AI Summary

Arcturus Therapeutics announced promising results from their Phase 1 and Phase 1b interim trials of ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis (CF). The trials, presented at the 47th European Cystic Fibrosis Conference, demonstrated that ARCT-032 is safe and well-tolerated with no serious adverse events reported. Among the 36 study participants, 4 adults with CF showed a +4.0% average absolute improvement in lung function (FEV1) and a +5.8% relative change on Day 8 after two doses. The data aligns with pre-clinical CF ferret model results. Participants with different CF mutations and those on Trikafta® showed favorable responses. Mild-to-moderate febrile reactions were noted in some healthy volunteers but were managed with albuterol. No serious adverse events or dose-limiting toxicities were observed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.31%
Tags
-
Rhea-AI Summary

Arcturus Therapeutics announced positive interim data for its inhaled investigational mRNA therapeutic, ARCT-032, targeting cystic fibrosis (CF). The Phase 1b trial showed an average 4% improvement in FEV1 among the first four CF patients after two administrations. The treatment was well tolerated with no serious adverse events. These results will be presented at the European Cystic Fibrosis Conference on June 7, 2024. This study supplements the favorable data from the Phase 1 single ascending dose study in healthy volunteers, indicating potential advancements for ARCT-032 in treating CF.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.31%
Tags
none
-
Rhea-AI Summary

CSL and Arcturus Therapeutics announced pivotal data published in Nature Communications demonstrating the efficacy and tolerability of their novel self-amplifying (sa-mRNA) COVID-19 vaccine, ARCT-154. The vaccine, the first of its kind approved in Japan, showed 100% efficacy against severe COVID-19 in healthy adults aged 18-59 and over 90% efficacy in older adults or those with comorbidities. The study, covering phases 1 through 3b, indicated that two 5 μg doses were well-tolerated and provided robust protection against multiple strains, including Omicron BA 4/5. The results underline the potential of the sa-mRNA technology to offer long-lasting immunity and superior protection compared to traditional mRNA vaccines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
covid-19
Rhea-AI Summary

CSL and Arcturus Therapeutics announced that Nature Communications published results from an integrated phase 1/2/3a/3b study on ARCT-154, a self-amplifying mRNA COVID-19 vaccine. The study demonstrates that two 5 μg doses of ARCT-154 were well-tolerated and provided significant protection against multiple COVID-19 strains. The vaccine showed 100% efficacy against severe COVID-19 in healthy individuals aged 18-59 and over 90% efficacy in at-risk populations. These results add to previous findings showing superior immunogenicity to Omicron BA 4/5 and longer-lasting immunity compared to conventional mRNA boosters. The vaccine's approval in Japan marks a significant milestone in the fight against COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
covid-19
-
Rhea-AI Summary

Arcturus Therapeutics (Nasdaq: ARCT), a global leader in mRNA medicines, announced its participation in several upcoming investor and scientific conferences. These include the TIDES USA on May 16, 2024, H.C. Wainwright BioConnect on May 20, 2024, Piper Sandler Lung Investor Conference on May 23, 2024, and Goldman Sachs Healthcare Conference on June 12, 2024. These events will feature presentations and fireside chats, providing the company with opportunities to showcase its advancements in infectious disease vaccines and treatments for liver and respiratory rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.12%
Tags
conferences
-
Rhea-AI Summary

Arcturus Therapeutics announces a positive first-quarter financial update and pipeline progress. The commercial manufacture of Kostaive is on track for the delivery of 4 million doses in Q3. The European Marketing Authorization decision is expected in Q3. Multiple Phase 3 trials demonstrate the breadth of the STARR vaccine platform. Important Phase 1 data for ARCT-2138 is anticipated in Q3. JP Morgan will monetize the company's investment in ARCALIS JV in Japan. Financially, revenues decreased due to the CSL agreement, while operating expenses increased. The net loss was $26.8 million, but the cash position remains strong, with a cash runway of at least three years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. will release its financial results for the first quarter of 2024 on May 8, 2024, focusing on mRNA medicines for infectious diseases and rare liver and respiratory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
conferences earnings

FAQ

What does Arcturus Therapeutics specialize in?

Arcturus Therapeutics specializes in developing RNA-based medicines for rare diseases, particularly focusing on liver and respiratory conditions.

What are the core technologies of Arcturus Therapeutics?

Arcturus' core technologies include the LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA).

What kind of diseases is Arcturus targeting with its therapies?

Arcturus targets rare diseases such as ornithine transcarbamylase deficiency, cystic fibrosis, and viral infections like influenza and COVID-19.

What recent collaborations has Arcturus entered into?

Arcturus has recently partnered with PassPort Technologies Inc. to explore innovative mRNA formulations and transdermal delivery methods for vaccines and therapeutics.

What is Kostaive®?

Kostaive® is the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine developed by Arcturus.

Who are Arcturus' major partners?

Arcturus collaborates globally with CSL Seqirus for mRNA vaccines and has a joint venture in Japan, ARCALIS, focusing on mRNA vaccine and therapeutic manufacturing.

What is LUNAR-OTC?

LUNAR-OTC is a therapeutic candidate in Arcturus' pipeline aimed at treating ornithine transcarbamylase deficiency.

How extensive is Arcturus' patent portfolio?

Arcturus holds over 400 patents and patent applications issued across the U.S., Europe, Japan, China, and other countries.

Where is Arcturus Therapeutics headquartered?

Arcturus is headquartered in San Diego, California.

How can I get more information about Arcturus Therapeutics?

For more detailed information, visit their official website at www.ArcturusRx.com, and connect with them on Twitter and LinkedIn.

Arcturus Therapeutics Holdings Inc.

Nasdaq:ARCT

ARCT Rankings

ARCT Stock Data

636.67M
26.93M
8.51%
98.9%
16.27%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO